Navigation Links
Pharmaxis Closes Share Purchase Plan
Date:6/29/2009

FDA or other regulatory approval or that we will seek any such approval. Factors that could cause or contribute to such differences include, but are not limited to, factors discussed in the "Risk Factors and Other Uncertainties" section of our Form 20-F lodged with the U.S. Securities and Exchange Commission.

    CONTACT:

     Alan Robertson
     Chief Executive Officer
     Tel:   +61-2-9454-7200
     Email: alan.robertson@pharmaxis.com.au

    RELEASED THROUGH:

     Australia:
     Felicity Moffatt
     Tel:   +61-418-677-701
     Email: felicity.moffatt@pharmaxis.com.au

     United States:
     Brandon Lewis
     Trout Group
     Tel:   +1-646-378-2915
     Email: blewis@troutgroup.com

'/>"/>
SOURCE Pharmaxis Ltd
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Pharmaxis Announces Placement of $47 Million and Share Purchase Plan
2. New Pharmaxis Board Appointment
3. Pharmaxis Investor Conference Call
4. Pharmaxis Appoints French Distributor for Aridol(TM)
5. Pharmaxis Builds Senior Management Team
6. Pharmaxis Investor Conference Call
7. Pharmaxis Aridol Approved for Sale in Switzerland
8. Pharmaxis Investor Conference Call
9. Pharmaxis Research Programs Highlighted at European Respiratory Society Congress
10. New Pharmaxis Board Appointment
11. Pharmaxis Aridol Authorised for Sale in Germany
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2015)... March 30, 2015  Naldemedine, an investigational peripherally ... Shionogi & Co., Ltd., met its primary and ... I) for the treatment of opioid-induced constipation (OIC) ... opioid therapy. Study results showed that naldemedine (0.2 ... the frequency of spontaneous bowel movement (SBM) compared ...
(Date:3/29/2015)... 2015 Caris Life Sciences® today ... showing the presence of PD-1 and PD-L1 ... Using Caris Molecular Intelligence®, the company,s panomic ... of programmed cell death protein-1 (PD-1) in ... its ligand (PD-L1) expression was variable across ...
(Date:3/27/2015)... -- Neogen Corporation (NASDAQ: NEOG ) announced today that ... in accordance with Securities and Exchange Commission rule 10b5-1. ... Corporation, is a minority owner of this entity that ... Herbert does not have control of this entity, but ... for a portion of the shares owned by that ...
(Date:3/27/2015)... 27, 2015  CASI Pharmaceuticals, Inc. (Nasdaq: CASI ... and commercialization of innovative therapeutics addressing cancer and other ... commercial focus on China , today ... ended December 31, 2014.  The Company ... per share, for the three months ended December 31, ...
Breaking Biology Technology:Shionogi & Co., Ltd. Announces That Naldemedine Meets Primary Endpoint In A Phase 3 Study For The Treatment Of Opioid-Induced Constipation 2Shionogi & Co., Ltd. Announces That Naldemedine Meets Primary Endpoint In A Phase 3 Study For The Treatment Of Opioid-Induced Constipation 3Caris Life Sciences' Multiplatform Tumor Profiling Technology Identifies Expression of PD-1 and PD-L1 in Gynecologic Malignancies 2Caris Life Sciences' Multiplatform Tumor Profiling Technology Identifies Expression of PD-1 and PD-L1 in Gynecologic Malignancies 3Caris Life Sciences' Multiplatform Tumor Profiling Technology Identifies Expression of PD-1 and PD-L1 in Gynecologic Malignancies 4Neogen CEO adopts 10b5-1 Trading Plan 2CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 2CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 3CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 4CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 5CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 6
... , , , , , , , ... Protocol No. 4308 915.522 03/2002 , , , , , ... , Microorganism , Mycobacterium smegmatis LR222, ... Bacteria, gram positive, , , ...
... , , , , , , , , ... Protocol No. 4308 915.521 02/2002 , , , , , ... , Microorganism , Mycobacterium intracellulare 1403, ... Bacteria, gram positive, , , ...
... , , , , , Multiporator / Electroporator 2510 , , , ... Transformation Protocol , Protocol No. 4308 915.520 12/2001 , ... , , , , ... , Cell type , Bacteria, gram ...
Cached Biology Technology:Mycobacterium smegmatis 2Mycobacterium intracellulare 2Listeria monocytogenes 2
(Date:3/11/2015)... , March 11, 2015   The Sync ... platform to scientifically measure and harness music to ... real-time biometrics and objective measurements of physiology, enabling ... at scale in large populations. It is designed ... and clinicians perform rigorous studies and accelerate the ...
(Date:3/10/2015)... Transforming How We Look at ... in Human Space Flight" by Michael A. ... Ph.D. was recently featured by Springer Science Media, highlighting the ... Specifically, "Personalized Medicine in Human Space Flight" was ... 2013 and 2014 from Springer in the journal ...
(Date:3/10/2015)... , March 10, 2015  NXT-ID, Inc. ... or the "Company"), a biometric authentication company focused ... company,s Wocket™ smart wallet has been named the ... Rethink Modern. Rethink Modern ( http://www.rethinkmodern.com/ ... innovative items for your home and lifestyle that have a ...
Breaking Biology News(10 mins):Introducing The Sync Project, a Global Collaboration Harnessing the Scientific Potential of Music for Health 2Introducing The Sync Project, a Global Collaboration Harnessing the Scientific Potential of Music for Health 3"Personalized Medicine in Human Space Flight" Listed Among Most Influential Papers of 2013 and 2014 2NXT-ID's Wocket Smart Wallet Named Number One Best Tech Gift for 2015 by Rethink Modern 2NXT-ID's Wocket Smart Wallet Named Number One Best Tech Gift for 2015 by Rethink Modern 3NXT-ID's Wocket Smart Wallet Named Number One Best Tech Gift for 2015 by Rethink Modern 4
... The first State of the Carbon Cycle Report for North ... Science Program, finds the continents carbon budget increasingly overwhelmed by ... tons of carbon into the atmosphere each year, mostly as ... may remove up to half this amount, but these current ...
... In the December 1st issue of G&D, Dr. Hailing ... of a new class of small RNAs in Arabidopsis. ... dubbed long short interfering RNAs (lsiRNAs), and are induced ... liRNAs share some hallmark features with other, previously identified ...
... Researchers from Kaiser Permanente and the California Department of ... nationwide, today will begin enrolling families in the largest ... that may cause autism and other developmental disabilities. ... Early Development, will involve 2,700 children and their parents ...
Cached Biology News:First-ever 'State of the Carbon Cycle Report' finds troubling imbalance 2Largest study to investigate risk factors of autism to begin enrolling families 2
... Level 2 Detection System combines the ... bonding principle and Signets unique formulation ... specificity and reliablility. Signet reagents will ... manual and automated protocols. ,Signets USA ...
... 2 Detection System combines the indirect ... principle and Signets unique formulation of ... and reliablility. Signet reagents will achieve ... and automated protocols. ,Signets USA Detection ...
... Level 2 Detection System combines the ... bonding principle and Signets unique formulation ... specificity and reliablility. Signet reagents will ... manual and automated protocols. ,Signets ...
Each bottle contains: Bromophenol Blue 0.25% w/v , Xylene Cyanol FF 0.25%, Glycerol solution 30% w/v...
Biology Products: